Detail akcie Ardelyx online

Business Summary: Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Ardelyx Inc revenues increased 27% to $94.5M. Net loss decreased 9% to $37.6M. Revenues reflect IBSRELA segment increase of 58% to $70.1M. Lower net loss reflects Stock-based Compensation in Research decrease of 28% to $2.6M (expense), Non cash interest expenses related to sa decrease of 36% to $1.3M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.17 to -$0.15.